MoonLake Immunotherapeutics MLTX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Long-Lived Assets by Geography | ||||||
| Portugal | $948K-22.5% | $1.02M-19.1% | $1.09M-4.6% | $1.16M+32.7% | $1.22M+34.1% | |
| Switzerland | $888K+64.7% | $322K-47.2% | $395K-42.0% | $468K-37.6% | $539K-34.2% | |
| United Kingdom | $553K-64.0% | $804K-54.8% | $1.05M-47.8% | $1.3M-42.3% | $1.54M-37.9% | |
| Number of operating leases by Geography | ||||||
| Portugal | 2+300% | 0.50.0% | 0.50.0% | 0.50.0% | 0.50.0% | |
| Switzerland | 2+300% | 0.50.0% | 0.50.0% | 0.50.0% | 0.50.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MoonLake Immunotherapeutics break its business down?
- MoonLake Immunotherapeutics (MLTX) reports long-lived assets by geography across 3 parts — Portugal, Switzerland and United Kingdom. Each is extracted from the segment footnotes and tracked over time.
- Where does MoonLake Immunotherapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MoonLake Immunotherapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.